FindTrial
Sign In

Comparative Study of Intravenous Single Doses of Palonosetron (PALO) With Granisetron Hydrochloride as a Control in Patients Receiving Highly Emetogenic Chemotherapy.

Comparative Study of Intravenous Single Doses of Palonosetron (PALO) With Granisetron Hydrochloride as a Control in Patients Receiving Highly Emetogenic Chemotherapy.

Status
Unknown
Phases
Phase 3
Study type
Interventional
Source
JPRN
Registry ID
JPRN-jRCT2080220284
Enrollment
Unknown
Registered
2006-07-31
Start date
2006-07-31
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute and delayed nausea and vomiting

Interventions

investigational material(s) Generic name etc : PALO INN of investigational material : palonosetron Therapeutic category code : 239 Other agents affecting digestive organs Dosage and Administration for

Sponsors

Taiho Pharmaceutical Co., Ltd.
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Acute and delayed nausea and vomiting induced by highly emetogenic chemotherapy.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Complete response (CR) rate for acute- and delayed-phase nausea and vomiting—

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026